Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited reported a third-quarter net profit attributable to shareholders of RMB224.6 million, up 54 per cent year-on-year, helped by a one-off gain from asset disposals and firmer industrial margins.

For the three months ended Sept 30, revenue fell 38 per cent to RMB1.02 billion as the wholesale unit Tianjin Zhongxin Medicine was deconsolidated. Despite the top-line contraction, earnings per share rose to RMB0.30 from RMB0.19.

The board will seek shareholder approval on Dec 15 for an interim cash dividend of RMB2.45 per share (RMB24.50 for every 10 shares). The payout will be subject to a 10 per cent withholding tax for S-shareholders; record and payment dates will be announced later.

Nine-month revenue slipped 35 per cent to RMB3.67 billion, while net profit soared to RMB2.15 billion from RMB803.9 million a year earlier. This jump was driven largely by a RMB1.54 billion gain on the sale of the remaining 12 per cent stake in former associate Sino-American Tianjin SmithKline & French Lab. Excluding this item, operating profitability was supported by a higher industrial gross margin of 73 per cent, up from 48 per cent.

By segment, Chinese medicine remained the core business, contributing revenue of RMB3.37 billion and gross profit of RMB2.64 billion for the nine-month period. The Western medicine segment generated RMB47.2 million in sales and RMB21.7 million in gross profit, while other operations delivered RMB257.7 million in revenue.

Marketing and distribution expenses declined 4 per cent to RMB1.42 billion over nine months, reflecting the absence of Tianjin Zhongxin Medicine. Finance costs dropped 97 per cent to RMB0.6 million after external borrowings were pared back.

The group ended September with RMB1.05 billion in cash, down from RMB2.94 billion at end-2024 after paying a RMB985.8 million final dividend and placing roughly RMB2.57 billion into higher-yielding deposit products.

Looking ahead, management pointed to policy support for traditional Chinese medicine, ongoing digitisation and supply-chain upgrades as tailwinds, while warning that volatile raw-material prices remain a near-term challenge. The company said it will continue to deepen its brand-led strategy, accelerate R&D focused on clinical value and expand new-retail channels to underpin long-term growth.